CDCP1 and melanoma: High levels of cell surface CD318 are associated with progressive disease and markedly poorer survival in breast (71), lung (72), colorectal (73), ovarian (74, 75), renal (76), prostate (77), melanoma (78), pancreatic (79), and hematopoietic cancers (80).